

Auspex Pharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 19-Jan-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

Auspex Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Auspex Pharmaceuticals Inc
Parent Company Name	Auspex Pharmaceuticals Inc
Website	http://www.auspexpharma.com/
Country	US
Number of Drugs in Active Development	7
Number of Inactive Drugs	3
Number of Patents as Owner	151
Number of Patents as Third Party	0
Number of Deals	2
Key Indications	Depression, Rheumatoid arthritis, Parkinsons disease, Huntingtons chorea, Schizophrenia, Asthma, Tardive dyskinesia, Tourette syndrome, Cancer, Neuropathic pain
Key Target-based Actions	Synaptic vesicular amine transporter inhibitor, JAK tyrosine kinase inhibitor, P2Y12 purinoceptor antagonist, Retinoic acid receptor agonist, Dopamine D2 receptor antagonist, Histamine H1 receptor antagonist, 5-HT 3 receptor antagonist, Beta 3 adrenoceptor modulator, Dopamine D2 receptor modulator, Potassium channel inhibitor
Key Technologies	Small molecule therapeutic, Oral formulation, Systemic formulation unspecified, Tablet formulation, Dermatological formulation, Prodrug, Oral controlled release formulation, Pharmaceutical carrier, Salt synthesis

COMPANY PROFILE

SUMMARY

Auspex Pharmaceuticals is a US pharmaceutical company that specializes in optimizing the chemo-physiological properties of existing drugs by converting them into deuterated analogs.

MERGERS & ACQUISITIONS

In January 2015, the company entered into a share purchase agreement to acquire the remaining rights to SD-1077, and related intellectual property, through the acquisition of Imphar AG. The company had previously granted Auspex exclusive US and select worldwide rights and retained European and additional worldwide rights, all of which were to be transferred to Auspex, along with the related intellectual property, pursuant to the share purchase agreement.

FINANCIAL

In December 2014, Auspex was added to the NASDAQ Biotechnology Index.

In July 2014, Auspex priced an underwritten public offering of 30.15 million shares of common stock at \$19.25 each and planned to raise gross proceeds of approximately \$60.6 million. The underwriters were granted a 30-day option to purchase up to an additional 472,500 shares of its common stock. Later that month, the offering was completed and the company raised gross proceeds of approximately \$69.7 million through 3,622,500 shares of its common stock including full exercise of the optional shares granted.

In March 2014, Auspex was added to the Russell 2000, Russell 3000 and Russell Global Indexes, at the close of market on March 31, 2014.

In February 2014, Auspex priced its IPO of 7 million shares of common stock at \$12 per share and granted underwriters a 30-day option to purchase up to an aggregate of 1.05 million additional shares. Auspex stock was to trade on the NASDAQ Global Market under the symbol 'ASPX'. At that time, the offering was expected to close on February 10, 2014. Later in February 2014, the IPO was completed and 8,050,000 common stock shares were issued, including 1,050,000 shares from full exercise of underwriters' option.

[Return to Table of Contents](#)



In January 2014, Auspex raised a total of \$35 million in two seperate financings, including \$20 million in a series E equity financing and a \$15 million four-year venture loan from Oxford Finance LLC.

In November 2012, Auspex raised \$25 million in a series D venture financing.

In May 2008, Auspex raised \$13.88 million from a series B financing round.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	59.65
Change (USD)	3.88 (6.96%)
Previous Close Price (USD)	55.77
Volume	260,152
52-Week High (USD)	62.00
52-Week Low (USD)	13.25
Date	16-Jan-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	27,582,400
Current Market Capitalization	1,645,290,160
EPS (Date Reported)	-0.00296

[Return to Table of Contents](#)

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Thomas, McNerney & Partners, MGT, LLC	Venture Capital	United States	5,270,604	19.11	50,380	0.01	07-Jan-2015
CMEA Capital	Venture Capital	United States	3,802,614	13.79	-114,143	-0.03	07-Jan-2015
Panorama Capital	Venture Capital	United States	2,770,589	10.04	0	0	07-Jan-2015
Shah (Pratik)	Individual Investor	United Kingdom	903,018	3.27	0	0	07-Jan-2015
Sarshar (Sepehr)	Individual Investor	United States	242,574	0.88	-356,876	-0.6	07-Jan-2015
Schmid (John P)	Individual Investor	United States	144,444	0.52	144,444	1	07-Jan-2015
Saks (Samuel R)	Individual Investor	United States	65,922	0.24	1,437	0.02	07-Jan-2015
Chowrira (Bharat M)	Individual Investor	United States	7,231	0.03	7,231	1	07-Jan-2015
Greer (R Scott)	Individual Investor	United States	7,190	0.03	7,190	1	07-Jan-2015

[Return to Table of Contents](#)

Proehl (Gerald T)	Individual Investor	United States	1,466	0.01	1,466	1	07-Jan-2015
Stamler (David A)	Individual Investor	United States	983	0	392	0.66	07-Jan-2015

FINANCIAL PERFORMANCE



	2012	2011	2013		
Sales (USD M)	0	0	0		
Operating Income (USD M)	-13.429	-5.973	-13.192		
Net Income (USD M)	-15.112	-2.814	-15.629		

[Return to Table of Contents](#)

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-13.909	-19.038
2014 Q2	0	-10.039	-10.385
2014 Q1	0	-6.106	-10.123
2013 Q4	0	-4.908	-7.589
2013 Q3	0	-2.837	-2.846
2013 Q2	0	-2.817	-2.889
2012 Q4	0	-3.383	-4.41

BALANCE SHEET

Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	3.162	4.279	36.65		
Inventories - Total	0	0	0		
Current Assets - Total	3.327	4.432	36.892		
Property, Plant And Equipment - Net	0.02	0.023	0.026		
Other Assets - Total	0.032	0.033	1.954		
Total Assets	3.379	4.488	38.872		

Liabilities (USD M)

	2011	2012	2013		
Accounts Payable	0.394	0.853	1.365		
Short Term Debt & Current Portion Of Long Term Debt	2.738	0			
Current Liabilities - Total	3.246	1.126	3.492		
Long Term Debt	0	0	14.42		
Other Liabilities	0.822	3.132	4.052		
Total Liabilities	4.068	4.258	21.964		

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	33.899	49.848	91.726		
Common Stock	0	0	0		
Treasury Stock	0	0			
Total Liabilities & Shareholders' Equity	3.379	4.488	38.872		

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-2.19	-2.08	-2.16
31-Dec-2016	-1.05	-0.92	-1.33
31-Dec-2017	1.18	0.69	0.04

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-61.56	0.67
31-Dec-2016			-32.77	53.51
31-Dec-2017			49.45	152.21


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	3	1	4
Cardiovascular disease	2	0	2
Psychiatric disorder	2	0	2
Inflammatory disease	2	0	2
Immune disorder	1	0	1
Respiratory disease	1	0	1
Genetic disorder	1	0	1
Musculoskeletal disease	1	0	1
Dermatological disease	0	1	1
Neoplasm	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	4
No Development Reported	3

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	1	0	1	0	2

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	3	6
Genetic disorder	0	2
Psychiatric disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	3
Phase 2	2	2
Phase 1	0	2
Phase not specified	0	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	52	0	52
Endocrine disease	39	0	39
Gastrointestinal disease	63	0	63
Genitourinary disease	43	0	43
Growth disorder	9	0	9
Hematological disease	13	0	13
Degeneration	19	0	19
Andrology	18	0	18
Immune disorder	54	0	54
Psychiatric disorder	51	0	51
Musculoskeletal disease	38	0	38
Neoplasm	38	0	38
Ocular disease	25	0	25
Genetic disorder	24	0	24
Metabolic disorder	39	0	39
Mouth disease	2	0	2
Neurological disease	82	0	82
Nutritional disorder	20	0	20
Prophylaxis	1	0	1
Respiratory disease	46	0	46
Infectious disease	34	0	34
Injury	15	0	15
Toxicity and intoxication	18	0	18
Inflammatory disease	53	0	53
Fatigue	1	0	1

[Return to Table of Contents](#)



Otorhinolaryngological disease	12	0	12
Gynecology and obstetrics	20	0	20
Temperature disorder	1	0	1
Dermatological disease	30	0	30
Ulcer	4	0	4
Surgical procedure	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

deutetrabenazine

Drug Name	deutetrabenazine
Key Synonyms	deutetrabenazine
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Tourette syndrome, Huntingtons chorea, Tardive dyskinesia, Heart disease
Target-based Actions	Synaptic vesicular amine transporter inhibitor
Other Actions	Monoamine release modulator, CNS modulator
Technologies	Oral formulation, Tablet formulation, Small molecule therapeutic
Last Change Date	15-Jan-2015

deuterated venlafaxine (neuropathic pain), Auspex

Drug Name	deuterated venlafaxine (neuropathic pain), Auspex
Key Synonyms	
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Depression, Neuropathic pain
Target-based Actions	
Other Actions	Radiopharmaceutical, Antidepressant, 5-HT uptake inhibitor, Norepinephrine uptake inhibitor, Analgesic
Technologies	Systemic formulation unspecified, Small molecule therapeutic
Last Change Date	09-Apr-2014

[Return to Table of Contents](#)



deuterated pirfenidone analog (idiopathic pulmonary fibrosis), Auspex

Drug Name	deuterated pirfenidone analog (idiopathic pulmonary fibrosis), Auspex
Key Synonyms	
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Idiopathic pulmonary fibrosis
Target-based Actions	
Other Actions	Fibrosuppressant, Unspecified drug target
Technologies	Systemic formulation unspecified, Small molecule therapeutic
Last Change Date	11-Nov-2014

deuterated ticagrelor analog (acute coronary syndrome), Auspex

Drug Name	deuterated ticagrelor analog (acute coronary syndrome), Auspex
Key Synonyms	
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Acute coronary syndrome
Target-based Actions	P2Y12 purinoceptor antagonist
Other Actions	Platelet aggregation inhibitor
Technologies	Small molecule therapeutic
Last Change Date	09-Apr-2014

[Return to Table of Contents](#)

deuterated tofacitinib analog (rheumatoid arthritis), Auspex

Drug Name	deuterated tofacitinib analog (rheumatoid arthritis), Auspex
Key Synonyms	
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Rheumatoid arthritis
Target-based Actions	JAK tyrosine kinase inhibitor
Other Actions	Anti-inflammatory
Technologies	Small molecule therapeutic
Last Change Date	09-Apr-2014

deuterated ketamine (oral, mood disorder), Auspex Pharmaceuticals

Drug Name	deuterated ketamine (oral, mood disorder), Auspex Pharmaceuticals
Key Synonyms	
Originator Company	Auspex Pharmaceuticals Inc
Active Companies	Auspex Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Mood disorder
Target-based Actions	
Other Actions	Antipsychotic, Unspecified drug target
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	09-Apr-2014

[Return to Table of Contents](#)

deuterated levodopa (Parkinson's disease), Auspex/Imphar

Drug Name	deuterated levodopa (Parkinson's disease), Auspex/Imphar
Key Synonyms	
Originator Company	Imphar AG
Active Companies	Auspex Pharmaceuticals Inc, Imphar AG
Inactive Companies	
Highest Status	Discovery
Active Indications	Parkinsons disease
Target-based Actions	
Other Actions	Antiparkinsonian, Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	13-Jan-2015

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

